Herold Advisors Inc. decreased its stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) by 33.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,000 shares of the company’s stock after selling 1,000 shares during the quarter. Herold Advisors Inc.’s holdings in BioNTech were worth $217,000 at the end of the most recent reporting period.
A number of other hedge funds have also bought and sold shares of the stock. Financial Gravity Asset Management Inc. acquired a new stake in shares of BioNTech in the second quarter worth $123,000. Eagle Bay Advisors LLC acquired a new stake in shares of BioNTech in the second quarter worth $33,000. State of Wyoming acquired a new stake in shares of BioNTech in the second quarter worth $26,000. EverSource Wealth Advisors LLC increased its stake in shares of BioNTech by 61.6% in the second quarter. EverSource Wealth Advisors LLC now owns 299 shares of the company’s stock worth $32,000 after acquiring an additional 114 shares during the period. Finally, Resurgent Financial Advisors LLC acquired a new stake in BioNTech during the fourth quarter valued at $47,000. Institutional investors and hedge funds own 15.52% of the company’s stock.
BioNTech Price Performance
Shares of BNTX stock opened at $93.14 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.38 and a quick ratio of 10.14. The firm’s 50-day moving average is $101.43 and its two-hundred day moving average is $104.41. BioNTech SE has a 12 month low of $88.00 and a 12 month high of $147.66. The company has a market capitalization of $22.14 billion, a PE ratio of 8.08 and a beta of 0.27.
Wall Street Analysts Forecast Growth
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
- Five stocks we like better than BioNTech
- How to Invest and Trade Chinese Stocks
- MarketBeat Week in Review – 2/5 – 2/9
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Cloudflare results spark analysts reset: 25% upside ahead
- What Are Growth Stocks and Investing in Them
- Beyond Nvidia: The hidden stars with 200% earnings growth
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.